Obsidian Therapeutics, Inc. OBX
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 0.95% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 28.90% | ||||
| Operating Income | -28.90% | ||||
| Income Before Tax | -31.74% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -31.74% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -31.74% | ||||
| EBIT | -28.90% | ||||
| EBITDA | -29.61% | ||||
| EPS Basic | 99.63% | ||||
| Normalized Basic EPS | 99.63% | ||||
| EPS Diluted | 99.63% | ||||
| Normalized Diluted EPS | 99.63% | ||||
| Average Basic Shares Outstanding | 35,074.35% | ||||
| Average Diluted Shares Outstanding | 35,074.35% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||